X hits on this document

37 views

0 shares

0 downloads

0 comments

4 / 6

Arias

Dovepress

slower but more sustained improvement in visual acuity and foveal thickness while those treated with bevacizumab demonstrated rapid improvement with a diminished effect over time.

A

Both agents were safe and well tolerated; neither ocular nor systemic complications were observed in any patient.

Illustrative cases of eyes treated with pegaptanib (Fig- ures 2 A–C and 3A, B) and bevacizumab (Figures 4A, B and 5A, B) are shown.

B

A

Basal: VA = 54 letters (20/80)

Month 1: VA = 45 letters (20/125)

Month 3: VA = 44 letters (20/125)

Month 6: VA = 42 letters (20/125)

Figure 3 A 76-year-old male patient having a disciform scar in the left eye and no prior treatments received 4 injections of pegaptanib. A) Fundus photograph at baseline (left panel) and fluorescein angiography (right panel). B) Optical coherence tomography images and visual acuity (VA; Early Treatment Diabetic Retinopathy Study [ETDRS] letters) at baseline and months 1, 3, and 6.

B

A

C

Basal: VA = 35 letters (20/200)

Month 1: VA = 52 letters (20/100)

B

Basal: VA = 60 letters (20/63)

Month 1: VA = 35 letters (20/200)

Month 3: VA = 53 letters (20/80)

Month 6: VA = 70 letters (20/40)

Month 3: VA = 45 letters (20/125)

Month 6: VA = 55 letters (20/80)

Figure 2 A 75-year-old female patient with previously untreated advanced age-related macular degeneration in the right eye received pegaptanib every 6 weeks for 3 injec- tions. A) Fundus photograph at baseline (left panel) and fluorescein angiography (right panel).B) Indocyanine green angiography at baseline and 6 months. C) Optical coher- ence tomography images and visual acuity (VA; EarlyTreatment Diabetic Retinopathy Study [ETDRS] letters) at baseline and months 1, 3, and 6.

Figure 4 An 80-year-old male patient with a disciform scar in the right eye received prior photodynamic therapy with verteporfin and 3 injections of bevacizumab. A) Fluorescein angiography. B) Optical coherence tomography images and visual acuity (VA; Early Treatment Diabetic Retinopathy Study [ETDRS] letters) at baseline and months 1, 3, and 6.

372

submit your manuscript | www.dovepress.com Dovepress

Clinical Ophthalmology 2010:4

Document info
Document views37
Page views37
Page last viewedMon Jan 16 15:59:22 UTC 2017
Pages6
Paragraphs177
Words3833

Comments